Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 27Leukemia, Myeloid, Chronic-Phase 9Breast Neoplasms 6Leukemia 5Philadelphia Chromosome 4Blast Crisis 4Neoplasms 3Bronchiolitis Obliterans Syndrome 3Neoplasm Metastasis 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Translocation, Genetic 1Thymus Neoplasms 1Thymoma 1Pathologic Processes 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Diseases 1Advanced Breast Cancer (Parts 1 and 2) 1

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Translocation, Genetic × bosutinib × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡